troponin C from bovine heart -Sepharose
- Known as:
- troponin C bovine heart -Sepharose
- Catalog number:
- T0094
- Product Quantity:
- 1 ml
- Category:
- -
- Supplier:
- BIO-VAR
- Gene target:
- troponin from bovine heart -Sepharose
Related genes to: troponin C from bovine heart -Sepharose
- Gene:
- MHRT NIH gene
- Name:
- myosin heavy chain associated RNA transcript
- Previous symbol:
- -
- Synonyms:
- Myheart
- Chromosome:
- 14q11.2
- Locus Type:
- RNA, long non-coding
- Date approved:
- 2014-09-17
- Date modifiied:
- 2017-07-24
Related products to: troponin C from bovine heart -Sepharose
(Ala11·22·28)_VIP (human, bovine, porcine, rat) Salt Trifluoroacetate Binding _ Synonym (Ala11·22·28)_Aviptadil SumFormula C139H231N43O39S(Ala11·22·28)_VIP (human, bovine, porcine, rat) Salt Trifluoroacetate Binding _ Synonym (Ala11·22·28)_Aviptadil SumFormula C139H231N43O39S(Ala13)-Apelin-13 (human, bovine, mouse, rat) 98% C63H107N23O16S CAS: 568565-11-7(Ala13)_Apelin_13 (human, bovine, mouse, rat) Salt Trifluoroacetate Binding _ Synonym SumFormula C63H107N23O16S(Ala13)_Apelin_13 (human, bovine, mouse, rat) Salt Trifluoroacetate Binding _ Synonym SumFormula C63H107N23O16S(Ala96)-Myelin Basic Protein (87-99) (human, bovine, rat) 98% C70H110N20O17 CAS:(Ala96)_Myelin Basic Protein (87_99) (human, bovine, rat) Salt _ Binding _ Synonym SumFormula C72H112N20O17(Ala96)_Myelin Basic Protein (87_99) (human, bovine, rat) Salt _ Binding _ Synonym SumFormula C72H112N20O17(b_Asp3)_VIP (human, bovine, porcine, rat) Salt Trifluoroacetate Binding _ Synonym (b_Asp3)_Aviptadil SumFormula C147H238N44O42S(b_Asp3)_VIP (human, bovine, porcine, rat) Salt Trifluoroacetate Binding _ Synonym (b_Asp3)_Aviptadil SumFormula C147H238N44O42S(D-Ala2,Met5)-β-Casomorphin (1-5) amide (bovine) 98% C31H42N6O6S CAS:(D-Lys16)-ACTH (1-24) (human, bovine, rat)
(D-Lys16)-Tetracosactide 98% C136H210N40O31S CAS: 494750-52-6(D-Lys16)-ACTH (1-24) human, bovine, mouse, ovine, porcine, rabbit, rat(D-Lys16)-ACTH (1-24) human, bovine, mouse, ovine, porcine, rabbit, rat(D-Lys16)-ACTH (1-24) human, bovine, mouse, ovine, porcine, rabbit, rat Related articles to: troponin C from bovine heart -Sepharose
- Moderately hypofractionated radiation therapy (MHRT) offers practical advantages for postoperative prostate cancer (PC) patients. However, concerns persist regarding long-term genitourinary (GU) toxicity. This prospective cohort study aims to evaluate late toxicities, disease control outcomes, and to identify predictors of late GU toxicity following MHRT. - Source: PubMed
Publication date: 2026/03/21
Ren Xue-YingQin Shang-BinLiu ChaoQi XinBai YunChen Jia-YanLyu FengGao YanLi Xiao-YingLi Hong-ZhenGao Xian-ShuMa Ming-Wei - Moderately hypofractionated radiotherapy (m-HRT) is a standard of care in the radical treatment of localized prostate cancer (PCa). Still, its role after radical prostatectomy (RP) is yet to be defined. We present long-term outcome and toxicity results of m-HRT in the post-prostatectomy setting. - Source: PubMed
Publication date: 2026/04/06
Camilli FedericoCaini SaverioDoccioli ChiaraSaldi SimonettaFesta EleonoraBecchetti Anna GiuliaGravante SabrinaMoretti RiccardoBellavita RitaAristei CynthiaIngrosso Gianluca - To determine the differences in rates of acute and late toxic effects, overall survival (OS), failure-free survival (FFS), and biochemical failure-free survival (BFS) between patients receiving ultra-hypofractionated radiation therapy (UHRT) vs conventionally fractionated radiotherapy (CFRT), UHRT vs moderate hypofractionated radiation therapy (MHRT), or MHRT vs CFRT. - Source: PubMed
Publication date: 2026/03/06
Mo ChunhaoChen ChuanjianFan LeiLi JiaweiFan NingDing Hui - Cervical cancer (CC) remains a leading cause of cancer-related mortality, particularly in low- and middle-income countries (LMICs), despite advancements in HPV vaccination and screening. Radiotherapy (RT) plays a critical role in managing CC, but conventional fractionated radiotherapy (CFRT) is limited by long treatment durations, which reduce patient adherence, increase the risk of treatment interruptions, and impair healthcare access in LMICs. Moderately hypofractionated radiotherapy (MHRT) may offer a promising alternative, delivering higher doses per fraction with fewer total fractions, thus shortening treatment duration and alleviating the burden on both patients and healthcare systems. Early clinical data suggest that MHRT achieve acceptable short- to medium-term tumor control with manageable toxicity. However, the small sample sizes and limited follow-up in published studies preclude definitive conclusions about long-term efficacy and safety. This review synthesizes the existing clinical evidence to outline the potential benefits and inherent limitations of MHRT in CC management and highlight the need for future large-scale, long-term randomized controlled trials with rigorous quality assurance protocols. These findings also have implications for the potential implementation of MHRT in LMICs. - Source: PubMed
Publication date: 2026/01/01
Xiao HuiGuo FuxinWang ZhenyuPei KangjiaWei ShuhuaQu AngWang JunjieJiang Ping - The technical advances allowed to take the leap towards hypofractionated schedules, as well as dose-escalated schedules, for prostate cancer (PCa) radiotherapy (RT). The aim of this systematic review is to describe RT techniques and toxicity outcomes within trials investigating hypofractionation, and to discuss current or future strategies to mitigate treatment-related toxicity. - Source: PubMed
Publication date: 2025/12/23
Le Guevelou JenniferZilli ThomasFerrario FedericaMurthy VedangTree AlisonLoblaw AndrewVan der Heide Uulke AKishan AmarDraulans CédricMartin JaradOst PietSargos Paul